Cabaletta Bio, Inc.
Develops engineered T cell therapies for B cell-mediated autoimmune diseases.
CABA | US
Overview
Corporate Details
- ISIN(s):
- US12674W1099
- LEI:
- Country:
- United States of America
- Address:
- 2929 ARCH STREET, 19104 PHILADELPHIA
- Website:
- https://www.cabalettabio.com/
Description
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company utilizes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) platform to develop treatments that aim to provide deep, durable, and potentially curative responses. Its lead product candidate, rese-cel, is a fully human CD19-CAR T cell therapy designed to transiently eliminate B cells, thereby enabling an "immune system reset." Rese-cel is being advanced in Phase 1/2 clinical trials for a range of autoimmune diseases, including systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cabaletta Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cabaletta Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cabaletta Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
